Clinical trials: Maculopathy
Minimal Change Disease (MCD), Membranous Nephropathy
Nephrotic Syndrome Study Network
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage…
- Conditions
- Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
- Trial name
- NEPTUNE (NCT01209000)
- Testing
- Kidney Biopsy
- Where
- 44 sites in United States, Canada
- Volunteers
- 1,200 people
- Sponsor
- University of Michigan
Ophthalmic Diseases (Specific Types Not Restricted), Cataract
Research on a New Intelligent Mobile Screening and Diagnosis Pattern for Ocular Diseases
The global distribution of primary ophthalmic medical resources is uneven, and the traditional eye disease screening model has problems such as low efficiency, high cost and limited coverage.
- Conditions
- Ophthalmic Diseases (Specific Types Not Restricted), Cataract, Refraction Error, Diabetic Retinopathy (DR)
- Trial name
- NCT07003165
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Macular Degeneration
Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy
This study will evaluate whether docosahexaenoic acid (DHA) dietary supplementation can improve macular function in patients with Stargardt macular dystrophy and Stargardt-like macular dystrophy.
- Trial name
- NCT00060749
- Testing
- Docosahexaenoic Acid (DHA) Dietary Supplement
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Eye Institute (NEI)
Regional Blood Flow
Choroidal Blood Flow and Progression of Age-Related Macular Degeneration in the Fellow Eye in Patients With Unilateral Choroidal Neovascularisation
Age-related macular degeneration (AMD) is the chief cause of severe and irreversible loss of vision in developed countries. The prevalence of AMD increases dramatically with age.
- Trial name
- NCT00808197
- Testing
- ocular blood flow measurement
- Where
- Austria
- Volunteers
- 41 people
- Sponsor
- Medical University of Vienna
Age Related Macular Degeneration
Treatment of AMD With Rheohemapheresis /RHF/
In this research rheohemapheresis will be used for the treatment of patients with high-risk dry form of age-related macular degeneration.
- Trial name
- TARHF (NCT01943396)
- Testing
- rheohemapheresis
- Where
- Czechia
- Volunteers
- 36 people
- Sponsor
- University Hospital Hradec Kralove
Macular Edema
Risk Factors for the Recurrent Postoperative Macular Edema Treated With OZURDEX
Patients who were diagnosed as postoperative CME and administrated with intravitreal OZURDEX injection were reviewed. Outcome will include best-corrected visual acuity (BCVA), intraocular pressure (IOP) and central macular…
- Trial name
- NCT05372562
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University
Diabetic Macular Edema
Bevacizumab Versus Combined Bevacizumab and Triamcinolone for Refractory Diabetic Macular Edema; a Randomized Clinical Trial
The purpose of this study is to compare the efficacy and safety of intravitreal injection of bevacizumab alone versus bevacizumab combined with triamcinolone for treatment of refractory diabetic macular edema.
- Trial name
- NCT00370422
- Testing
- Triamcinolone, Bevacizumab
- Where
- Iran
- Sponsor
- Shahid Beheshti University of Medical Sciences
Age-related Macular Degeneration (AMD)
Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device
The investigators would like to know if different imaging devices can improve the quality of images and visualization of imaged tissues.
- Trial name
- NCT02445313
- Testing
- Nidek MP-3
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Doheny Image Reading Center
Stargardt Disease
Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease
A Phase 1/2, open-label, non-randomized, dose-escalation study, where a minimum of 9 and a maximum of 18 eligible patients with Stargardt Disease will be enrolled sequentially in up to 3 dose cohorts of RTx-021.
- Trial name
- AURORA (NCT07439887)
- Testing
- RTx-021
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ray Therapeutics, Inc.
Choroidal Neovascularization, Macular Degeneration
Fluocinolone Implant to Treat Macular Degeneration
This study will test the safety and effectiveness of a fluocinolone implant to treat age-related macular degeneration. This eye disease can severely impair central vision, affecting a person's ability to read, drive, and carry…
- Trial name
- NCT00008515
- Testing
- Fluocinolone
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Eye Institute (NEI)
pMN, IgAN
Atacicept in Multiple Glomerular Diseases
A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.
- Conditions
- pMN, IgAN, Nephrotic Syndrome, MCD
- Trial name
- NCT06983028
- Testing
- Atacicept
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Vera Therapeutics, Inc.
Stargardt Disease, Stargardt Macular Dystrophy
A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions
Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye.
- Conditions
- Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
- Trial name
- DEVOTE (NCT07734064)
- Testing
- ASP2020
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Astellas Institute for Regenerative Medicine
Retinal Dystrophy, Cone-Rod, Cone Dystrophy
Study of New Mutations in Cone Disorders
High throughput sequencing gives the opportunity to improve the genetic diagnosis for patients suffering from retinal dystrophies and specially from cone disorders.
- Conditions
- Retinal Dystrophy, Cone-Rod, Cone Dystrophy, Cone Rod Dystrophy, Macular Degeneration
- Trial name
- INTROCONE (NCT04658251)
- Testing
- Blood and/or skin biopsy
- Where
- France
- Volunteers
- 7 people
- Sponsor
- University Hospital, Lille
Non-Proliferative Diabetic Retinopathy
Intravitreal and Intracameral DEX in NPDR
To investigate the effects of intravitreal and intracameral injection of dexamethasone during cataract phacoemulsification in patients with mild to moderate non-proliferative diabetic retinopathy
- Trial name
- NCT06951087
- Testing
- Dexamethasone sodium phosphate
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Affiliated Hospital of Nantong University
Stargardt Disease
Study of ALK-001 on the Progression of Stargardt Disease
This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)
- Trial name
- NORTHSTAR (NCT07419334)
- Testing
- ALK-001
- Where
- 14 sites in United States
- Volunteers
- 230 people
- Sponsor
- Alkeus Pharmaceuticals, Inc.
Age-Related Macular Degeneration
Effects of Xanthophylls on Optical Density
The objective of the study was to investigate the influence of a intervention with lutein und zeaxanthin from crucifers on the optical density of the macular pigment of patients with non exudative age-related maculopathy.
- Trial name
- NCT01316198
- Testing
- Verum
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University of Jena
Maculopathy
Assessment Of Diabetic Maculopathy Changes After Phacoemulsification by Using Optical Coherence Tomography
Investigators aimed to assess the macular changes with OCT after uncomplicated phacoemulsification surgery in diabetic patients with non proliferative diabetic retinopathy (NPDR) at the time of surgery and the effect of…
- Trial name
- Maculopathy (NCT05547789)
- Testing
- non steroidal anti inflammatory drugs
- Where
- 2 sites in Egypt
- Volunteers
- 30 people
- Sponsor
- Assiut University
Stargardt Disease 1, STGD1
A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants
This is a first-in-human (FIH), multicenter, randomized, double-masked, placebo-controlled adaptive clinical study evaluating the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of CITY-RBP4, following…
- Conditions
- Stargardt Disease 1, STGD1, Healthy Volunteers
- Trial name
- NCT07836452
- Testing
- CITY-RBP4
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- City Therapeutics
Macular Degeneration, Age-Related Macular Degeneration
The Focal Electro-Oculogram in Macular Disease
Background: Maculopathies are eye conditions that affect the center of the retina. Retina health depends on the retinal pigment epithelium (RPE), a layer behind the retina.
- Trial name
- NCT02225119
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Eye Institute (NEI)
Age-Related Macular Degeneration
Beovu Experience UZ Leuven
Reporting early real-world clinical data of consecutive patients on the use of Beovu® (brolucizumab) intravitreal injections in patients with neovascular age-related macular degeneration.
- Trial name
- BEL (NCT05220085)
- Testing
- Brolucizumab Ophthalmic Dbll 6 Mg/0.05 mL Intravitreal Solution
- Where
- Belgium
- Volunteers
- 17 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven